Breaking News

Northwest Awards Synteract Management of Brain Cancer Trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Northwest Biotherapeutics, Inc. awarded a contract to Synteract for the clinical trial management of its Phase II trial to evaluate DCVax-Brain in patients with Glioblastoma multiforme. DCVax-Brain is a personalized therapeutic cancer vaccine using the patient’s own dendritic cells (immune cells) with the patient’s own tumor biomarkers (antigens). “We are pleased to be working with Synteract in this important clinical trial given their longstanding expertise in successful ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters